Neocardial Technologies
NeoCardial Technologies™, a Minneapolis-based medical device company, innovates heart failure treatment with its unique eHeart™ device.
Founded
2014NeoCardial Technologies™, a Minneapolis-based medical device company, innovates heart failure treatment with its unique eHeart™ device.
NeoCardial Technologies, LLC, is a Minneapolis-based medical device company founded to innovate and improve treatment options for patients suffering from late-stage heart failure. The company's core mission is to extend and enhance the lives of these underserved patients through advanced medical solutions. NeoCardial's flagship product, the eHeart™, is a non-blood contact, direct compression, extra-ventricular circulatory support device designed to provide immediate cardiac output assistance. This device is implanted via a thoracotomy procedure and aims to offer a less invasive and more effective alternative to existing treatments.
The team behind NeoCardial Technologies includes highly skilled professionals from medical, scientific, engineering, and entrepreneurial backgrounds, each with a history of success in their respective fields. The company has garnered attention for its innovative approach to heart failure treatment and has made significant strides in the medical device industry. NeoCardial's impact is marked by its commitment to addressing critical gaps in heart failure care, potentially improving outcomes and quality of life for many patients.
Companies similar to Neocardial Technologies include NeoChord, Phoenix Cardiac, MedNews and Native Cardio.
Neocardial Technologies was founded in 2014.
Neocardial Technologies' headquarters is located in Minneapolis, MN, US.
Neocardial Technologies' most recent funding round was for $125k (USD) in December 2019.
As of Dec 31, 2019, Neocardial Technologies has raised a total of $125k (USD).
Neocardial Technologies has 5 employees as of Feb 4, 2024.
MedNews
